Crinetics Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016
Net Income	-214.53	-163.92	-107.64	-73.81	-50.42	-27.12	-9.16	-6.02
Depreciation & Amortization	2.31	1.39	1.26	1.23	1.11	0.47	0.13	0.09
Share-Based Compensation	40.94	28.27	17.35	10.43	6.29	2.32	0.27	0.27
Other Operating Activities	4.98	19.06	0.44	0.13	-3.37	4.87	-0.72	0.19
Operating Cash Flow	-166.31	-115.21	-88.59	-62.03	-46.38	-19.46	-9.48	-5.47
Capital Expenditures	-4.69	-1.66	-0.44	-0.19	-0.49	-1.06	-0.3	-0.19
Acquisitions	-5	0	0	0	0	0	0	0
Change in Investments	-190.73	-172.32	-56.05	0.4	42.16	-118.4	0	0
Investing Cash Flow	-200.41	-173.98	-56.48	0.22	41.67	-119.46	-0.3	-0.19
Share Issuance / Repurchase	388.94	121.96	252.68	114.57	0.07	106.92	0.07	0
Debt Issued / Paid	0	0	0	0	0	0	-0.21	-0.05
Other Financing Activities	-	-	-	-	-	63.28	11.97	-0.01
Financing Cash Flow	388.94	121.96	252.68	114.57	0.07	170.2	11.82	-0.05
Net Cash Flow	22.22	-167.22	107.61	52.76	-4.65	31.28	2.04	-5.71
Free Cash Flow	-171	-116.86	-89.02	-62.21	-46.87	-20.52	-9.78	-5.66
Free Cash Flow Margin	-4261.03%	-2466.98%	-8258.26%	-87623.94%	-3929.00%	-845.06%	-478.39%	-960.61%
Free Cash Flow Per Share	-2.94	-2.25	-2.32	-2.04	-1.94	-1.69	-7.14	-5.60

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).